Exosome-Encased Nucleic Acid Scaffold Chemotherapeutic Agents for Superior Anti-Tumor and Anti-Angiogenesis Activity

被引：5

作者：

McNamara, Ryan P. ^{[1
,2
]}

Eason, Anthony B. ^{[1
,2
]}

Zhou, Yijun ^{[1
,2
]}

Bigi, Rachele ^{[1
,2
]}

Griffith, Jack D. ^{[1
,2
]}

Costantini, Lindsey M. ^{[1
,2
,3
]}

Rudek, Michelle A. ^{[4
]}

Anders, Nicole M. ^{[4
]}

Damania, Blossom A. ^{[1
,2
]}

Dittmer, Dirk P. ^{[1
,2
]}

机构：

[1] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[2] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA

[3] North Carolina Cent Univ, Dept Biol & Biomed Sci, Durham, NC 27707 USA

[4] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA

来源：

ACS BIO & MED CHEM AU | 2022年 / 2卷 / 02期

关键词：

exosome; extracellular vesicles; drug delivery; Kaposi's sarcoma; virology; PEGYLATED-LIPOSOMAL DOXORUBICIN; EXTRACELLULAR VESICLES; COMMUNICATION; FLUORESCENCE; PACLITAXEL; DELIVERY; SARCOMA;

D O I：

10.1021/acsbiomedchemau.1c00030

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Extracellular vesicles(EVs), or exosomes, play a pivotal rolein tumor growth and metastasis, such as in the case of Kaposi Sarcoma.By loading tumor-derived EVs with chemotherapeutic drugs, we notedthat their pro-tumor/pro-angiogenic phenotype was converted into ananti-tumor phenotype in vivo. Drug concentrationin EVs was significantly higher than in clinically approved liposomeformulation, as retention was facilitated by the presence of miRNAsinside the natural EVs. This demonstrates a new mechanism by whichto increase the payload capacity of nanoparticles. By exploiting thetargeting preferences of tumor-derived EVs, chemotherapeutics canbe directed to specifically poison the cells and the microenvironmentthat enables metastasis.

引用

页码：140 / 149

页数：10

共 50 条

[21] Cell shrinkage, cell cycle arrest and anti-angiogenesis underlie the anti-tumor activity of the mTOR inhibitor AP23573.
Pollock, R
Rivera, VM
Tang, H
Berk, L
Gaschet, J
Metcalf, CA
Clackson, T
CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6176S - 6176S
[22] Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model
Yan, Xiaojun
Chen, Haimin
Lu, Xiaoling
Wang, Feng
Xu, Weifeng
Jin, Haixiao
Zhu, Peng
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 43 (04) : 251 - 259
[23] MUTAGENIC ACTIVITY OF NITROSOUREA ANTI-TUMOR AGENTS
FRANZA, BR
OESCHGER, NS
OESCHGER, MP
SCHEIN, PS
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1980, 65 (01) : 149 - 154
[24] CYCLOSPORINS - IMMUNOSUPPRESSIVE AGENTS WITH ANTI-TUMOR ACTIVITY
KREIS, W
SORICELLI, A
EXPERIENTIA, 1979, 35 (11): : 1506 - 1508
[25] Anti-tumor activity of the novel angiogenesis inhibitor anginex
Dings, RPM
van der Schaft, DWJ
Hargittai, B
Haseman, J
Griffioen, AW
Mayo, KH
CANCER LETTERS, 2003, 194 (01) : 55 - 66
[26] COLLABORATION BETWEEN SPECIFIC ANTI-TUMOR IMMUNITY AND CHEMOTHERAPEUTIC-AGENTS
YAMAMURA, Y
PROCTOR, JW
FISCHER, BC
HARNAHA, JB
MAHVI, TA
INTERNATIONAL JOURNAL OF CANCER, 1980, 25 (03) : 417 - 423
[27] Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities
Sheu, JR
Fu, CC
Tsai, ML
Chung, WJ
ANTICANCER RESEARCH, 1998, 18 (6A) : 4435 - 4441
[28] Anti-tumor chemotherapeutic agents induce developmental disorders of tooth germ
Yamamoto, Toshiro
Kita, Masakazu
Mori, Masahiko
Akamatsu, Yuki
Ichioka, Hiroaki
Iehara, Tomoko
Hosoi, Hajime
Kanamura, Narisato
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY MEDICINE AND PATHOLOGY, 2012, 24 (04) : 208 - 212
[29] Endothelial microparticles levels as markers of tumor response to treatment with anti-angiogenesis agents
Tillo, O.
Xiao, Y.
Cawkwell, L.
Maraveyas, A.
THROMBOSIS RESEARCH, 2010, 125 : S182 - S182
[30] Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor
Dongchun Wang
Feng Tang
Sen Wang
Zhenzhou Jiang
Luyong Zhang
Cancer Chemotherapy and Pharmacology, 2012, 69 : 173 - 183

← 1 2 3 4 5 →